Henri Roché
DuPont
157 Papers
1.6K Citations
Henri Roché is an academic researcher from DuPont. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 40, co-authored 154 publications. Previous affiliations of Henri Roché include University of Newcastle.
Chat about Author
Papers
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K. Litton,Hope S. Rugo,Johannes Ettl,Sara A. Hurvitz,Anthony Gonçalves,Kyung Hun Lee,Louis Fehrenbacher,Rinat Yerushalmi,Lida A. Mina,Miguel Martin,Henri Roché,Young-Hyuck Im,Ruben G.W. Quek,Denka Markova,Iulia Cristina Tudor,Alison L. Hannah,Wolfgang Eiermann,Joanne L. Blum +17 more
TL;DR: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single‐agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression‐free survival.
1.7K
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
TL;DR: The PACS 01 trial as mentioned in this paper compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycle of docetaxel as adjuvant treatment for node-positive early breast cancer.
601
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
- 01 Jan 2006
TL;DR: Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.
377
Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial
Jacques Bonneterre,Henri Roché,Pierre Kerbrat,Alain Brémond,Pierre Fumoleau,Moïse Namer,Marie-Josèphe Goudier,Simon Schraub,Pierre Fargeot,Isabelle Chapelle-Marcillac +9 more
TL;DR: Treatment with adjuvant FEC 100 demonstrated superior DFS and OS versus FEC 50 at 10 years of follow-up, and was not offset by long-term complications such as cardiac toxicity and second malignancy.
289
Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics
Etienne Chatelut,Pierre Canal,Valérie Brunner,Christine Chevreau,A. Pujol,Andrée Boneu,Henri Roché,Georges Houin,Roland Bugat +8 more
TL;DR: This method of prediction was as accurate as the one derived from the measurement of glomerular filtration rate following the injection of 51 chromium-EDTA and can permit individualized determination of carboplatin dosage in adults by simply multiplying the calculatedcarboplatin clearance by the area under the curve for the desired dosage administration.
249